Podcasts about usmani

Dr. Monty Pal speaks with internationally acclaimed hematologists Dr. Vincent Rajkumar and Dr. Saad Usmani about the AQUILA trial in high-risk smoldering multiple myeloma, as well as advances in CAR-T and other evolving treatment strategies in the myeloma space. TRANSCRIPT Dr. Monty Pal: Hello everyone and welcome to the ASCO Daily News Podcast. I'm your host, Monty Pal. I'm a medical oncologist, underline medical oncologist, a professor, and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. You're going to understand why I underlined "medical oncologist" there. I'm actually on the line today with two amazing hematologists. Today, we're going to actually explore treatments for high-risk smoldering multiple myeloma following the FDA's approval last year of daratumumab for the first-ever treatment of this indication. Now, this is based on the AQUILA trial, and this represents a huge shift in our traditional watch-and-wait approach to active disease interception. We're going to consider whether this landmark trial published in The New England Journal translates to day-to-day practice. I think it does, and we'll certainly make an argument for that. And I'm so fortunate today to have two internationally acclaimed experts here in the conversation: Dr. Vincent Rajkumar, senior author on the manuscript, and Dr. Saad Usmani, also an expert in his own right in myeloma. Dr. Rajkumar is the lead investigator of the AQUILA study. He's a professor of medicine and consultant in the divisions of hematology and hematopathology at the Mayo Clinic in Rochester, Minnesota. He actually chairs the Myeloma, Amyloidosis, Dysproteinemia Program. He is also editor-in-chief of the Blood Cancer Journal. Dr. Usmani, he and I actually go way, way back. We actually did the AACR Molecular Biology in Clinical Oncology course, I want to say in 2006, so this is our 20-year anniversary, Saad. He's the chief of the myeloma service at the MSK Cancer Center and a professor of medicine at the Weill Cornell Medical College in New York.  Saad, Vincent, welcome. Dr. Saad Usmani: Thank you so much for having me, Monty. Dr. Vincent Rajkumar: Yeah, thanks, Monty. A pleasure to be here. Dr. Monty Pal: Thanks. And just a quick note for our listeners, all of our disclosures are available in the transcript of this episode. First off, Saad, did I get that right? Was it 2006 when we did that course together? Dr. Saad Usmani: Yeah, 20 years. We are coming up to our 20-year anniversary. It's remarkable to have seen our careers move the way they have, Monty. Dr. Monty Pal: Oh my gosh. And for all the fellows who are on the line, that AACR Molecular Biology and Clinical Oncology course, it's sometimes overlooked. Wonderful primer on translational science. Okay, now we're going to get to the heart of the matter here, the AQUILA trial. So this was a study, Vincent, that you led. I wonder if you'd walk us through the primary endpoints in the study. What are we looking at in the AQUILA trial specifically? Dr. Vincent Rajkumar: Thanks so much. Again, as you mentioned, smoldering multiple myeloma has just been a condition that we watch and wait. And the first thing that I want to clarify here is that the AQUILA trial is looking at only a subset of smoldering multiple myeloma. That is the high-risk smoldering multiple myeloma. It was defined the way high-risk smoldering myeloma was defined at the time the trial was designed. It randomized 390 patients. One arm got daratumumab single agent in an attempt to delay progression to active myeloma and possibly prolong survival. And the other arm was the traditional observation. The primary endpoint, therefore, was time to active multiple myeloma. Other endpoints included time to when patients needed to start therapy for active multiple myeloma, which can vary based on physician judgment, and overall survival. Of course, response rate, complete response rate, and others were also endpoints. Dr. Monty Pal: That's interesting. And you know, I wanted you to riff a little bit on this definition of high-risk smoldering myeloma. Can you tell our audience how that's sort of evolved over the years? Dr. Vincent Rajkumar: Yes. I mean, if you step back, monoclonal gammopathy of undetermined significance has only a 1% per year risk of progression. Smoldering multiple myeloma, all comers have a 10% per year risk of progression. And over the years, trials have been done in the whole population, and then more recently, we felt we should really focus on the people with high-risk smoldering, defined as a 50-50 risk of progression in 2 years. That's like a 25% per year risk of progression in the first 2 years, which is a very high risk for the patient and something that would justify prophylactic intervention. And that definition initially was based on just high levels of monoclonal protein like more than 3 grams, the IgA subtype of myeloma, the suppression of uninvolved immunoglobulins. Others have used bone marrow flow cytometry markers, cytogenetics. Those combinations of factors were available at the time the AQUILA trial was designed, and a select combination was used. Later on, we found that we could match almost all of that in a very simple risk stratification using just the percentage of bone marrow plasma cells, the level of the M-spike, and the free light chain ratio, all three of which are available to all patients with smoldering at the time of diagnosis. So you don't need any special testing. So more than 20% plasma cells, more than 20 for the light chain ratio, and more than 2 grams for the M-spike. If someone has any two of the three, that is high-risk smoldering multiple myeloma according to the IMWG, but that definition, of course, came in 2020 after the AQUILA trial completed accrual. Dr. Monty Pal: That's interesting because this sort of flips the traditional paradigm where biomarkers get more and more complex as time goes on. Am I right in saying this sort of simplifies things a little bit? It uses standard laboratory or clinical parameters to gauge this category? Dr. Vincent Rajkumar: Absolutely. People were using suppression of uninvolved immunoglobulins, and those levels are not standardized, often vary by race. Also, the other aspect was the abnormal plasma cells on flow cytometry. Again, labs define it differently. So this makes it much more simple. But the IMWG also did a separate exploratory cohort within that paper where we added cytogenetics and we added scoring systems to improve on this further. So it simplified it for regular clinical practice and for like trials. But if you have a patient in front of you, the IMWG paper also has more complex scoring systems where you can take more than 20; 21 is more than 20, so is 51. And so, you can use the actual numbers that a patient has, additional variables like cytogenetics, and get a more refined estimate of what is the true risk of progression. Dr. Monty Pal: That's really helpful. Now, you told us about the primary endpoints, you've helped us define high-risk smoldering myeloma. Can you give us a sense of the top-line results from AQUILA? Dr. Vincent Rajkumar: Yes, I think the most important one was the primary endpoint, time to multiple myeloma, was at 5 years, the progression-free survival was 63% in the daratumumab arm compared to 41% in the observation arm. So, you know, approximately 60% of patients in the observation arm had already progressed by 5 years. And that number was about 40% for the daratumumab arm. We also looked at time to starting myeloma therapy, which is clinically actually quite meaningful because, you know, myeloma therapy means patients get a quadruplet for induction, they get stem cell transplant, they get endless maintenance, they get ongoing therapy virtually for the entire duration. So, preventing the need for myeloma therapy is in and of itself, I think, a major endpoint. And that at 3 years, 40% of people in the observation arm required full myeloma therapy compared to only 20% in the daratumumab arm. So there's a significant reduction in the risk of developing active myeloma as well as the need for myeloma therapy by using a time-limited 3 years of daratumumab single agent. Dr. Monty Pal: Perfect summary of the results. And maybe, Saad, I'm going to bring you into the conversation now. How does this sort of influence your day-to-day practice for smoldering myeloma? Is this something that you've incorporated for that high-risk subset? Dr. Saad Usmani: Thank you, Monty, and I agree. I think that's a really nice summary from Vincent. This study is very important for several reasons. It's actually the third clinical trial that has demonstrated that patients who are in the high-risk smoldering myeloma category benefit from an early intervention that delays the progression to active myeloma or to end-organ damage. And so having a nuanced discussion with our patients in the clinic becomes very important. Having this discussion around as an option becomes very important. And like Vincent said, when we look at that high-risk smoldering myeloma patient population, someone who has 22, 23% plasma cells versus, you know, 45, 50, you know, it's going to be a different discussion each time. But I think it's a very important first step. And I think this sets up the stage for us to design clinical trials where we can ask other questions on what would be better than daratumumab alone in terms of delaying progression in these patients. The other thing that I do want to highlight, and Vincent touched upon this a little bit, that the treatment in this clinical trial was for a fixed duration of treatment. So it was not forever treatment. This is maybe something that Vincent, you can even comment on a little bit more because the question we get after having this discussion is, "Okay, what do we do with patients who are going to be progressing to active myeloma?" Whether we can utilize anti-CD38 therapies for those. So Vincent, I would love your take on this too. Dr. Vincent Rajkumar: Yeah, I think, you know, the main philosophical change for me was previously, the thing was 'don't treat', and now for high-risk smoldering multiple myeloma, the question is, is daratumumab the best treatment or can we do something better? And those trials are thankfully ongoing. One of them has already completed accrual, isatuximab-len-dex versus len-dex. And another one is ongoing in ECOG, almost close to finishing accrual. And in the future, we'll be trying to see if we can use early intervention to even cure and prevent progression altogether.  So we are in this phase where we have one approved regimen, one approved drug, and we are not sure whether we can improve on that. The question is, "is a myeloma-like therapy better than monotherapy" would be the next question, and then what would we do further beyond that? In this context, whenever we have patients like this, one of the questions that comes up, as Saad mentioned, is how does this affect newly diagnosed myeloma therapy if somebody has been treated for smoldering and things like that? How will they be considered for clinical trials? Would they be considered as relapse myeloma or still newly diagnosed myeloma? And those are important discussions for clinical trialists to keep in mind, but I think for clinical practice, your duty is to the patient in front of you. If they have high-risk smoldering myeloma and there's data that there's treatments that can delay progression significantly, delay the need for myeloma therapy significantly, that's the highest priority. We'll cross that bridge.   There are so few patients going on clinical trials right now that if such a patient were to later on progress and wants to enter in a newly diagnosed myeloma trial later, years later, we can figure that out later. I feel like the most important discussion is what to do for that patient today. I still prefer a clinical trial if one was available. If one was not available, I'd prefer early intervention, but have an informed discussion with the patient because some of them may wish to delay therapy still. Some of them may have very borderline numbers that you want to watch them closely. Some of them may be having other comorbidities that prevent need for therapy. Some of them maybe have had the smoldering for a long time and you already know it's stable. So a lot of factors go in, and I think it's not a one-size-fits-all. Dr. Monty Pal: This is a terrific discussion, and you know, it sort of segues into maybe a question around biology. And this is something I was going to get to a little bit later, but Saad, I'm glad you brought it up. I'll liken it to the only thing I know, which is kidney cancer. So, you know, in kidney cancer, we use checkpoint inhibitors as adjuvant therapy. And there's this question of whether or not it breeds some resistance in the localized setting to ultimately what the patient might potentially be exposed to in the metastatic setting. Tell me your thoughts on this, Vincent, then maybe Saad separately. If you treat a patient with daratumumab in this high-risk smoldering setting, could it theoretically sort of limit options in the refractory setting now that we have regimens like DRBD that are kind of being utilized, or daratumumab with teclistamab? Vincent, I'll throw that to you first. Dr. Vincent Rajkumar: This is a great question, and it's usually asked when we've done the lenalidomide trials actually. We try to put the question back. If that was your concern, how would you actually solve it? Is it really biology that's going to answer that? Or is it a randomized trial? So the experiment has been done three times now where early intervention has been given. And if there was some detriment because of that, that would be reflected in the overall survival. In all three trials, there's no such detriment seen. In the first lenalidomide-dex trial, there was an improvement in overall survival. In the AQUILA trial again, the confidence interval doesn't cross one, and patients had better long-term survival on AQUILA, but certainly not less. We've also examined PFS2 data, and that doesn't seem to be affected. So yes, there is a theoretical concern, and that concern cannot be allayed for new treatments which we have not even tried, like tec-dara, and whether that effect would be there or not. But so far, I don't see it. And I think the onus is on proof of that in order to prevent people from getting early therapy. Dr. Monty Pal: Yeah. Saad, your thoughts on that? And before you jump in, I'll mention, we're kind of taking the same approach in kidney cancer, we're trying to really do studies to see whether or not, you know, immunotherapy rechallenge in these contexts, you know, really lends any substantial benefit. So far, the results have been interesting. I don't think we have enough numbers as yet to capture the impact of adjuvant therapy as it translates to metastatic, but I see so many similarities between the scenarios that you're facing in myeloma and what we're facing in RCC. Saad, your thoughts? Dr. Saad Usmani: Thanks, Monty. I'll go back to something that Vincent alluded to a few minutes ago about the way that we risk-stratify patients within smoldering myeloma. Right now, we are relying more on a disease burden-based stratification looking at the percentage of plasma cells in the bone marrow, the monoclonal protein, as well as the involved light chain versus the uninvolved light chain ratio. However, there are efforts underway to actually incorporate genomics into that schema and try to refine that definition of high-risk smoldering. And there have been two papers that came out in the latter half of last year. In fact. Dr. Rajkumar and I are co-senior authors on one effort where we can identify genomic myeloma in patients in precursor conditions. One of the key things that came out of that effort was that within the high-risk smoldering myeloma category, about 90% of the patients are genomically myeloma. So this whole debate of whether we need to intervene for those patients, I think, you know, we have sufficient biologic evidence that yes, we need to intervene for those patients.  I think that the next real step, like Vincent stated, is how do we intervene in those patients? And those clinical trials kind of are ongoing. We will probably need to have more validation of those genomic models being incorporated, but that's what I see in the future. I wouldn't be concerned for the patients being seen today with that query about the disease biology evolving because if I'm seeing a patient today in March of the first quarter of 2026 and offering them monotherapy daratumumab in their high-risk smoldering situation for the next 3 years and then they progress to myeloma after another couple of years, we are talking about what would be the treatment options for them in 2031, 2032. So I think the field is moving so fast, we have a lot of novel therapies coming into that frontline setting rapidly, so our options at that time would be very different. So, you know, I just wanted to kind of set up the stage for saying, you know, our tools are getting better in delineating which patients will need that intervention. And then eventually, I think, you know, we'll have much better options for newly diagnosed myeloma patients at the time when they need it in the future. Dr. Monty Pal: Just absolutely brilliant, absolutely brilliant. I love that summary. I think that you're absolutely right in saying that, you know, you've got to think about what you're going to do for that patient sort of in the moment, what's going to optimize their outcome and agree that the landscape is evolving very rapidly.  I'd be remiss, Saad, if I didn't ask you about something that I've been following in terms of your career trajectory. You've developed quite a reputation for your leadership in trials looking at CAR T-cell therapies for myeloma. Can you give us a sense of where that stands in broad terms? Dr. Saad Usmani: Certainly, Monty. I think the CAR Ts have slowly made their way from late relapse to early relapse. And now we have clinical trials that have completed accrual in the frontline setting comparing them to standard-of-care treatment for both older myeloma patients or transplant-ineligible patients, as well as younger transplant-eligible patients where we're actually trying to replace transplants with BCMA-directed CAR T-cell therapies. The nuance there would be we want to equal or better the survival outcomes that we've accomplished without compromising on the safety side of things for patients. Those therapies are moving into earlier lines. And more excitingly, you know, that's just the first wave of CARs. The next wave of CAR technology is coming, and it's going to be in vivo CARs where we may not need lymphodepleting chemotherapy, we may not even need as stringent regulatory nuances that we do for cellular therapies today. So, you know, I think the field is moving rapidly, and it's going to be a very interesting landscape to see over the next 5 to 6 years. Dr. Monty Pal: Yeah, you know, it's so interesting. I know in the solid tumor space, we're trying to replicate the success that you've had with CAR T and bispecifics, and I do see some light at the end of the tunnel. I'm seeing some really promising agents being developed, but clearly, we have so much to learn from our colleagues in hematology. Well, I have to tell you, this has just been a phenomenal conversation. Vincent, congratulations on your leadership of the AQUILA trial. Clearly, a big paradigm shift in the field. Saad, thank you for offering your expert insights and really giving us also a glimpse at the future of myeloma. Really appreciate having you both on the podcast today. Dr. Vincent Rajkumar: Thank you, Monty. Dr. Saad Usmani: Thank you so much. Dr. Monty Pal: And thank you so much to our listeners for your time today. Finally, if you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:      Dr. Monty Pal    @montypal   Dr. Vincent Rajkumar @VincentRK Dr. Saad Z. Usmani @szusmani   Follow ASCO on social media:           ASCO on X     ASCO on Bluesky          ASCO on Facebook           ASCO on LinkedIn           Disclosures:        Dr. Monty Pal:      Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview      Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical    Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis    Dr. Vincent Rajkumar: Honoraria: Research to Practice, Medscape Patents, Royalties, Other Intellectual Property: Authorship Royalties from Up To Date Dr. Saad Usmani: Consulting or Advisory Role: Janssen Oncology, GlaxoSmithKline, Abbvie, Bristol-Myers Squibb/Celgene, Regeneron, AstraZeneca, Sanofi Research Funding: Janssen Oncology, Bristol-Myers Squibb, K36 Therapeutics, Abbvie, Regeneron  

In today's episode, we welcomed Saad Z. Usmani, MD, MBA, FACP, FASCO, to discuss the significance of the January 2026 FDA approval of daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd) for the treatment of adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT).Usmani is chief of Myeloma Service at Memorial Sloan Kettering Cancer Center in New York, New York, and the recipient of the 2025 Giants of Cancer Care award for multiple myeloma.In the exclusive interview, Dr Usmani explained the clinical implications of the regulatory decision that expanded the indication for daratumumab plus VRd to the transplant-ineligible setting, detailed the pivotal data from the phase 3 CEPHEUS trial (NCT03652064) that supported the approval, and provided context for treatment strategies with this regimen in clinical practice.

So i was just sifting through some poetry online, and i came across a sherYe qadam qadam balayen, ye sawaad e ku e jaanaa.nWo yahin se laut jaaye jise zindagi ho pyaariNow i had often heard this sher being used in mushairas and other public settings, but never really knew who the author of this famous couplet was. It was Maulana Aamir Usmani. A poet that in my ignorance had never heard of before.Turns out, he was quite the maverick. Schooled from Deoband, even sold kites for a living once, wrote for bollywood, and many such feats. Khair. I finally got to this nazm of his; and what a nazm it is. Such a morning call to everyone who thinks the world was much better before and its just gone to the dogs now. Listen for yourself.If you want to talk, i am aamir@urdudaan.inHappy listening :)

Dr Saad Zafar Usmani from Memorial Sloan Kettering Cancer Center in New York discusses available data guiding treatment decision-making for patients with newly diagnosed multiple myeloma. CME information and select publications here.

Featuring an interview with Dr Saad Zafar Usmani, including the following topics: Optimizing treatment intervention for patients with newly diagnosed multiple myeloma (MM) (0:00) Role of anti-CD38 antibodies in induction and maintenance therapy for patients with newly diagnosed disease (4:22) Case: A woman in her late 70s with revised International Staging System (R-ISS) Stage II IgG kappa myeloma who received D-Rd followed by maintenance daratumumab (14:02) Case: A man in his early 60s with double-hit myeloma who received D-KRd and carfilzomib maintenance therapy (26:10) Case: A man in his early 70s with R-ISS Stage III IgG kappa myeloma and translocation (4;14) who deferred transplant (33:24) Future directions in the management of MM (40:37) CME information and select publications  

Featuring a slide presentation and related discussion from Dr Saad Zafar Usmani, including the following topics: Evolution of therapeutic decision-making for patients with newly diagnosed multiple myeloma (MM) (0:00) Quadruplet therapy for transplant-eligible patients with newly diagnosed MM (6:26) Daratumumab with lenalidomide as maintenance therapy after transplant in newly diagnosed MM (16:16) Therapeutic options for transplant-ineligible patients with MM (19:51) CME information and select publications

Dr Saad Zafar Usmani from Memorial Sloan Kettering Cancer Center in New York discusses available data guiding treatment decision-making for patients with newly diagnosed multiple myeloma. CME information and select publications here.

On this episode of "The HemOnc Pulse," Saad Usmani, MD, of the Memorial Sloan Kettering Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss notable presentations on multiple myeloma from the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.

Join us on the latest episode, hosted by Jared S. Taylor! Our Guest: Osama Usmani, CEO at Salubrum.What you'll get out of this episode:Introduction to Salubrum: Osama Usmani explains how Salubrum aims to revolutionize medical tourism by making the North American healthcare system more accessible to international care options.Beyond Cosmetic Surgery: Medical tourism extends far beyond cosmetic procedures, offering significant savings on essential treatments like IVF and stem cell therapy.Bridging the Gap: Salubrum focuses on creating digital tools that facilitate smoother communication between patients, payers, and providers, enhancing the medical tourism experience.Strategic Partnerships: Salubrum partners with major players like Quirón Salud and Definitive Healthcare to develop patient-provider links and expand distribution in North America.To learn more about Salubrum:Website https://www.salubrum.com/ LinkedIn https://www.linkedin.com/company/salubrum/ Guest's Socials:LinkedIn https://www.linkedin.com/in/osamau/ Our sponsors for this episode are:Sage Growth Partners https://www.sage-growth.com/Quantum Health https://www.quantum-health.com/Show and Host's Socials:Slice of HealthcareLinkedIn: https://www.linkedin.com/company/sliceofhealthcare/Jared S TaylorLinkedIn: https://www.linkedin.com/in/jaredstaylor/WHAT IS SLICE OF HEALTHCARE?The go-to site for digital health executive/provider interviews, technology updates, and industry news. Listed to in 65+ countries.

Host: Saad Z. Usmani, MD, MBA, FACP Guest: Joshua Richter, MD Guest: Ashley Steinberger, APP Release date: 8/15/2024Expiration date: 8/15/2025Estimated time to complete: 1.0 hour This activity is not accredited for CME/CE credit. This episode of Myeloma Matters reviews the latest data on bispecific antibody therapy for relapsed/refractory multiple myeloma (RRMM) discussed at the 2024 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings, including information about the use of fixed-duration dosing to mitigate adverse events (AEs). The program includes in-depth discussion and analysis of the latest scientific findings and practice-changing advances in managing RRMM. Expert faculty will place abstract findings into clinical context and discuss strategies for preventing and managing AEs associated with bispecific antibody therapy in RRMM treatment, which include cytokine release syndrome (CRS), neurotoxicity, and infection.

Do we understand racism as the primary driving engine of American inequality? Or do we focus instead on the indirect ways that frequently hard-to-discern class inequality and inegalitarian power relations can produce racially differentiated outcomes? Adaner Usmani, Assistant Professor of Sociology and Social Studies at Harvard and on the editorial board at Catalyst joined Elizabeth and John back in Fall, 2020, to wrestle with the subtle and complex genealogy of Southern plantation economy and its racist legacy. Adaner offers a complex genealogy of violence, mass incarceration and their roots in the social inequity (and iniquity) of antebellum economic relations. He emphasizes a frequently overlooked fact that a century ago Du Bois had already identified a key issue: the belatedness of African-American access to the social mobility offered by the North's industrialization, thanks to structures of a racist Southern agricultural economy that kept African-American workers away from those high-wage jobs. The result? An explanation for racial injustice that hinges on ossified class imbalances--contingent advantages for certain groups that end up producing (rather than being produced by) bigotry and prejudice. Adaner Usmani and John Clegg, "The Economic Origins of Mass Incarceration" (Catalyst 3:3, 2019) Michelle Alexander, The New Jim Crow: Mass Incarceration in the Age of Colorblindness (2010) Robin Einhorn, American Taxation, American Slavery (2006) Richard Rothstein, The Color of Law (2017) Kenneth Jackson, Crabgrass Frontier (1987) Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/african-american-studies

Do we understand racism as the primary driving engine of American inequality? Or do we focus instead on the indirect ways that frequently hard-to-discern class inequality and inegalitarian power relations can produce racially differentiated outcomes? Adaner Usmani, Assistant Professor of Sociology and Social Studies at Harvard and on the editorial board at Catalyst joined Elizabeth and John back in Fall, 2020, to wrestle with the subtle and complex genealogy of Southern plantation economy and its racist legacy. Adaner offers a complex genealogy of violence, mass incarceration and their roots in the social inequity (and iniquity) of antebellum economic relations. He emphasizes a frequently overlooked fact that a century ago Du Bois had already identified a key issue: the belatedness of African-American access to the social mobility offered by the North's industrialization, thanks to structures of a racist Southern agricultural economy that kept African-American workers away from those high-wage jobs. The result? An explanation for racial injustice that hinges on ossified class imbalances--contingent advantages for certain groups that end up producing (rather than being produced by) bigotry and prejudice. Adaner Usmani and John Clegg, "The Economic Origins of Mass Incarceration" (Catalyst 3:3, 2019) Michelle Alexander, The New Jim Crow: Mass Incarceration in the Age of Colorblindness (2010) Robin Einhorn, American Taxation, American Slavery (2006) Richard Rothstein, The Color of Law (2017) Kenneth Jackson, Crabgrass Frontier (1987) Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Do we understand racism as the primary driving engine of American inequality? Or do we focus instead on the indirect ways that frequently hard-to-discern class inequality and inegalitarian power relations can produce racially differentiated outcomes? Adaner Usmani, Assistant Professor of Sociology and Social Studies at Harvard and on the editorial board at Catalyst joined Elizabeth and John back in Fall, 2020, to wrestle with the subtle and complex genealogy of Southern plantation economy and its racist legacy. Adaner offers a complex genealogy of violence, mass incarceration and their roots in the social inequity (and iniquity) of antebellum economic relations. He emphasizes a frequently overlooked fact that a century ago Du Bois had already identified a key issue: the belatedness of African-American access to the social mobility offered by the North's industrialization, thanks to structures of a racist Southern agricultural economy that kept African-American workers away from those high-wage jobs. The result? An explanation for racial injustice that hinges on ossified class imbalances--contingent advantages for certain groups that end up producing (rather than being produced by) bigotry and prejudice. Adaner Usmani and John Clegg, "The Economic Origins of Mass Incarceration" (Catalyst 3:3, 2019) Michelle Alexander, The New Jim Crow: Mass Incarceration in the Age of Colorblindness (2010) Robin Einhorn, American Taxation, American Slavery (2006) Richard Rothstein, The Color of Law (2017) Kenneth Jackson, Crabgrass Frontier (1987) Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/history

Do we understand racism as the primary driving engine of American inequality? Or do we focus instead on the indirect ways that frequently hard-to-discern class inequality and inegalitarian power relations can produce racially differentiated outcomes? Adaner Usmani, Assistant Professor of Sociology and Social Studies at Harvard and on the editorial board at Catalyst joined Elizabeth and John back in Fall, 2020, to wrestle with the subtle and complex genealogy of Southern plantation economy and its racist legacy. Adaner offers a complex genealogy of violence, mass incarceration and their roots in the social inequity (and iniquity) of antebellum economic relations. He emphasizes a frequently overlooked fact that a century ago Du Bois had already identified a key issue: the belatedness of African-American access to the social mobility offered by the North's industrialization, thanks to structures of a racist Southern agricultural economy that kept African-American workers away from those high-wage jobs. The result? An explanation for racial injustice that hinges on ossified class imbalances--contingent advantages for certain groups that end up producing (rather than being produced by) bigotry and prejudice. Adaner Usmani and John Clegg, "The Economic Origins of Mass Incarceration" (Catalyst 3:3, 2019) Michelle Alexander, The New Jim Crow: Mass Incarceration in the Age of Colorblindness (2010) Robin Einhorn, American Taxation, American Slavery (2006) Richard Rothstein, The Color of Law (2017) Kenneth Jackson, Crabgrass Frontier (1987) Learn more about your ad choices. Visit megaphone.fm/adchoices

Do we understand racism as the primary driving engine of American inequality? Or do we focus instead on the indirect ways that frequently hard-to-discern class inequality and inegalitarian power relations can produce racially differentiated outcomes? Adaner Usmani, Assistant Professor of Sociology and Social Studies at Harvard and on the editorial board at Catalyst joined Elizabeth and John back in Fall, 2020, to wrestle with the subtle and complex genealogy of Southern plantation economy and its racist legacy. Adaner offers a complex genealogy of violence, mass incarceration and their roots in the social inequity (and iniquity) of antebellum economic relations. He emphasizes a frequently overlooked fact that a century ago Du Bois had already identified a key issue: the belatedness of African-American access to the social mobility offered by the North's industrialization, thanks to structures of a racist Southern agricultural economy that kept African-American workers away from those high-wage jobs. The result? An explanation for racial injustice that hinges on ossified class imbalances--contingent advantages for certain groups that end up producing (rather than being produced by) bigotry and prejudice. Adaner Usmani and John Clegg, "The Economic Origins of Mass Incarceration" (Catalyst 3:3, 2019) Michelle Alexander, The New Jim Crow: Mass Incarceration in the Age of Colorblindness (2010) Robin Einhorn, American Taxation, American Slavery (2006) Richard Rothstein, The Color of Law (2017) Kenneth Jackson, Crabgrass Frontier (1987) Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/critical-theory

Do we understand racism as the primary driving engine of American inequality? Or do we focus instead on the indirect ways that frequently hard-to-discern class inequality and inegalitarian power relations can produce racially differentiated outcomes? Adaner Usmani, Assistant Professor of Sociology and Social Studies at Harvard and on the editorial board at Catalyst joined Elizabeth and John back in Fall, 2020, to wrestle with the subtle and complex genealogy of Southern plantation economy and its racist legacy. Adaner offers a complex genealogy of violence, mass incarceration and their roots in the social inequity (and iniquity) of antebellum economic relations. He emphasizes a frequently overlooked fact that a century ago Du Bois had already identified a key issue: the belatedness of African-American access to the social mobility offered by the North's industrialization, thanks to structures of a racist Southern agricultural economy that kept African-American workers away from those high-wage jobs. The result? An explanation for racial injustice that hinges on ossified class imbalances--contingent advantages for certain groups that end up producing (rather than being produced by) bigotry and prejudice. Adaner Usmani and John Clegg, "The Economic Origins of Mass Incarceration" (Catalyst 3:3, 2019) Michelle Alexander, The New Jim Crow: Mass Incarceration in the Age of Colorblindness (2010) Robin Einhorn, American Taxation, American Slavery (2006) Richard Rothstein, The Color of Law (2017) Kenneth Jackson, Crabgrass Frontier (1987) Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/sociology

Do we understand racism as the primary driving engine of American inequality? Or do we focus instead on the indirect ways that frequently hard-to-discern class inequality and inegalitarian power relations can produce racially differentiated outcomes? Adaner Usmani, Assistant Professor of Sociology and Social Studies at Harvard and on the editorial board at Catalyst joined Elizabeth and John back in Fall, 2020, to wrestle with the subtle and complex genealogy of Southern plantation economy and its racist legacy. Adaner offers a complex genealogy of violence, mass incarceration and their roots in the social inequity (and iniquity) of antebellum economic relations. He emphasizes a frequently overlooked fact that a century ago Du Bois had already identified a key issue: the belatedness of African-American access to the social mobility offered by the North's industrialization, thanks to structures of a racist Southern agricultural economy that kept African-American workers away from those high-wage jobs. The result? An explanation for racial injustice that hinges on ossified class imbalances--contingent advantages for certain groups that end up producing (rather than being produced by) bigotry and prejudice. Adaner Usmani and John Clegg, "The Economic Origins of Mass Incarceration" (Catalyst 3:3, 2019) Michelle Alexander, The New Jim Crow: Mass Incarceration in the Age of Colorblindness (2010) Robin Einhorn, American Taxation, American Slavery (2006) Richard Rothstein, The Color of Law (2017) Kenneth Jackson, Crabgrass Frontier (1987) Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/american-studies

Do we understand racism as the primary driving engine of American inequality? Or do we focus instead on the indirect ways that frequently hard-to-discern class inequality and inegalitarian power relations can produce racially differentiated outcomes? Adaner Usmani, Assistant Professor of Sociology and Social Studies at Harvard and on the editorial board at Catalyst joined Elizabeth and John back in Fall, 2020, to wrestle with the subtle and complex genealogy of Southern plantation economy and its racist legacy. Adaner offers a complex genealogy of violence, mass incarceration and their roots in the social inequity (and iniquity) of antebellum economic relations. He emphasizes a frequently overlooked fact that a century ago Du Bois had already identified a key issue: the belatedness of African-American access to the social mobility offered by the North's industrialization, thanks to structures of a racist Southern agricultural economy that kept African-American workers away from those high-wage jobs. The result? An explanation for racial injustice that hinges on ossified class imbalances--contingent advantages for certain groups that end up producing (rather than being produced by) bigotry and prejudice. Adaner Usmani and John Clegg, "The Economic Origins of Mass Incarceration" (Catalyst 3:3, 2019) Michelle Alexander, The New Jim Crow: Mass Incarceration in the Age of Colorblindness (2010) Robin Einhorn, American Taxation, American Slavery (2006) Richard Rothstein, The Color of Law (2017) Kenneth Jackson, Crabgrass Frontier (1987) Learn more about your ad choices. Visit megaphone.fm/adchoices

Please visit answersincme.com/AEP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in myeloma discusses strategies to integrate novel anti-CD38 monoclonal antibody (mAb)-based triplet regimens into care plans for patients with early relapse multiple myeloma (MM). Upon completion of this activity, participants should be better able to: Review the latest evidence-based guideline recommendations for the treatment of early relapse MM; Outline the clinical implications of the latest evidence for anti-CD38 mAb-based triplet regimens in the treatment of early relapse MM; and Identify strategies to optimally integrate novel anti-CD38 mAb-based triplet regimens into treatment plans for patients with early relapse MM.

Dr Usmani details the FDA approval of cilta-cel for patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy.

Engineer Muhammad Ali --- Send in a voice message: https://podcasters.spotify.com/pod/show/muhammad-imran984/message

Saad Usmani, MD, MBA, FACP, Chief of the Myeloma Service at the Memorial Sloan Kettering Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, on The HemOnc Pulse to chat about the latest research in multiple myeloma from the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. Dr. Usmani shares insights on the evolution in myeloma treatment since he first started practicing in the hematologic oncology space. He also reflects on the Perseus and IsKia trials, which were presented at ASH 2023.

In this part 8 of Experiments that changed fire science series we revisit Cardington (previously covered in part 2 - https://www.firescienceshow.com/078-experiments-that-changed-fire-science-pt-2-bre-cardington-with-tom-lennon/), but this time from the perspective of modeling the structure. My guest prof. Asif Usmani of the HK PolyU takes us on how simplifying the model led them to some fundamental discoveries on the thermo-mechanical response of structures to fires.We discuss material properties and perhaps their overestimated role in structural modelling. We go into membrane actions and the role of restraints in shaping the response of beams and slabs to thermal loads. And Asif explains to me what this means at a scale of a building frame. Some truly remarkable insights - things that today are perhaps obvious to any structural engineer, but at that time were an unknown fire behaviour. Here are some links to the papers related to today's episode:Cardingtonhttps://www.sciencedirect.com/science/article/pii/S0379711201000376https://www.sciencedirect.com/science/article/pii/S0143974X01000049https://www.sciencedirect.com/science/article/pii/S0379711204000116WTChttps://era.ed.ac.uk/handle/1842/1562OpenSeeshttps://link.springer.com/article/10.1007/s10694-021-01184-0https://www.researchgate.net/profile/Xu-Dai-4/publication/283796522_OpenSees-based_integrated_tool_for_modelling_structures_in_fire/links/5647a6b108ae451880ac4f18/OpenSees-based-integrated-tool-for-modelling-structures-in-fire.pdfPicture credit: British Steel, after "Newman G, Robinson JT and Bailey CG, Fire safe design: A new approach to multi-storey steel-framed buildings, The Steel Construction Institute, Berkshire, 2006" Accessed through:  https://www.researchgate.net/publication/303531122_Shear_panel_component_in_the_vicinity_of_beam-column_connections_in_fire [accessed Dec 06 2023]. 

Sabah Usmani joins the Agents of Change in Environmental Justice podcast to discuss the role of urban planners in tackling environmental injustice.

Please visit answersincme.com/GQB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in hematology-oncology discuss B-cell maturation antigen (BCMA)–targeted therapies in the treatment of relapsed/refractory multiple myeloma. Upon completion of this activity, participants should be better able to: Identify where BCMA-targeted therapies fit into the current treatment paradigm of RRMM; Describe the clinical profiles of new and emerging BCMA-targeted bispecific antibodies in heavily treated RRMM; and Outline strategies to optimally incorporate novel BCMA-targeted bispecific antibodies into the treatment paradigm of RRMM.

Please visit answersincme.com/GQB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in hematology-oncology discuss B-cell maturation antigen (BCMA)–targeted therapies in the treatment of relapsed/refractory multiple myeloma. Upon completion of this activity, participants should be better able to: Identify where BCMA-targeted therapies fit into the current treatment paradigm of RRMM; Describe the clinical profiles of new and emerging BCMA-targeted bispecific antibodies in heavily treated RRMM; and Outline strategies to optimally incorporate novel BCMA-targeted bispecific antibodies into the treatment paradigm of RRMM.

Dr Usmani discusses the integration of elranatamab, talquetamab, and telcistamab into the management of relapsed/refractory multiple myeloma, common adverse effects and recommended supportive care measures, and ongoing research that may help clarify their role in the paradigm.

Clive Anderson and Michelle McManus are joined by Eddi Reader, Sumayya Usmani, Ben Hart and Kieran Hodgson for an eclectic mix of conversation, music and comedy.

Inside the Issue: Integrating Bispecific Antibodies into the Management of Multiple Myeloma — Patient Selection and Toxicity Management | Faculty Presentation 2: Tolerability and Other Practical Considerations with Bispecific Antibodies for MM CME information and select publications  

Is Thomas Piketty the world's most famous economic historian ? A superstar enemy of plutocratic capitalism who wrote a pathbreaking bestseller, Capital in the 21st Century? Or simply a debonair and generous French intellectual happy to talk redistributive justice? Join this 2020 conversation with John and Adaner Usmani (star of RTB's episode 44: Racism as idea, Racism as Power Relation) to find out. Why did we invite him? John thinks nobody is better than Piketty at mapping and explaining the nature and origin of the glaring and growing inequality that everywhere defines wealth distribution in the 21st century—both between societies and within them. His recent magnum opus, Capital and Ideology. ask what sorts of stories societies (and individuals within those societies) tell themselves so as to tolerate such inequality—and the poverty and misery it produces. Or even to see that inequality as part of the natural order of things. Why did he accept our invitation? A mystery, but who are we to look a gift economist in the mouth? Mentioned in the Episode Philip Larkin, “Why aren't they screaming?” (from the poem “The Old Fools”) Bonus: Here is John's question about his favorite writer, the one Adaner teased him for not asking: “Mr. Piketty, you are interested in hinge points where people cease being captivated by one ideology and begin seeing differently (might one also say, begin being captivated by another ideology?) In 2014, Ursula le Guin said: ‘We live in capitalism. Its power seems inescapable. So did the divine right of kings. Any human power can be resisted and changed by human beings. Resistance and change often begin in art, and very often in our art, the art of words.‘ Can I ask how that resonates with your argument about the rapid changeability of economic paradigms–and moral paradigms for justifying inequality–in Capital and Ideology? “ Read transcript here Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Is Thomas Piketty the world's most famous economic historian ? A superstar enemy of plutocratic capitalism who wrote a pathbreaking bestseller, Capital in the 21st Century? Or simply a debonair and generous French intellectual happy to talk redistributive justice? Join this 2020 conversation with John and Adaner Usmani (star of RTB's episode 44: Racism as idea, Racism as Power Relation) to find out. Why did we invite him? John thinks nobody is better than Piketty at mapping and explaining the nature and origin of the glaring and growing inequality that everywhere defines wealth distribution in the 21st century—both between societies and within them. His recent magnum opus, Capital and Ideology. ask what sorts of stories societies (and individuals within those societies) tell themselves so as to tolerate such inequality—and the poverty and misery it produces. Or even to see that inequality as part of the natural order of things. Why did he accept our invitation? A mystery, but who are we to look a gift economist in the mouth? Mentioned in the Episode Philip Larkin, “Why aren't they screaming?” (from the poem “The Old Fools”) Bonus: Here is John's question about his favorite writer, the one Adaner teased him for not asking: “Mr. Piketty, you are interested in hinge points where people cease being captivated by one ideology and begin seeing differently (might one also say, begin being captivated by another ideology?) In 2014, Ursula le Guin said: ‘We live in capitalism. Its power seems inescapable. So did the divine right of kings. Any human power can be resisted and changed by human beings. Resistance and change often begin in art, and very often in our art, the art of words.‘ Can I ask how that resonates with your argument about the rapid changeability of economic paradigms–and moral paradigms for justifying inequality–in Capital and Ideology? “ Read transcript here Learn more about your ad choices. Visit megaphone.fm/adchoices

Is Thomas Piketty the world's most famous economic historian ? A superstar enemy of plutocratic capitalism who wrote a pathbreaking bestseller, Capital in the 21st Century? Or simply a debonair and generous French intellectual happy to talk redistributive justice? Join this 2020 conversation with John and Adaner Usmani (star of RTB's episode 44: Racism as idea, Racism as Power Relation) to find out. Why did we invite him? John thinks nobody is better than Piketty at mapping and explaining the nature and origin of the glaring and growing inequality that everywhere defines wealth distribution in the 21st century—both between societies and within them. His recent magnum opus, Capital and Ideology. ask what sorts of stories societies (and individuals within those societies) tell themselves so as to tolerate such inequality—and the poverty and misery it produces. Or even to see that inequality as part of the natural order of things. Why did he accept our invitation? A mystery, but who are we to look a gift economist in the mouth? Mentioned in the Episode Philip Larkin, “Why aren't they screaming?” (from the poem “The Old Fools”) Bonus: Here is John's question about his favorite writer, the one Adaner teased him for not asking: “Mr. Piketty, you are interested in hinge points where people cease being captivated by one ideology and begin seeing differently (might one also say, begin being captivated by another ideology?) In 2014, Ursula le Guin said: ‘We live in capitalism. Its power seems inescapable. So did the divine right of kings. Any human power can be resisted and changed by human beings. Resistance and change often begin in art, and very often in our art, the art of words.‘ Can I ask how that resonates with your argument about the rapid changeability of economic paradigms–and moral paradigms for justifying inequality–in Capital and Ideology? “ Read transcript here Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/critical-theory

Is Thomas Piketty the world's most famous economic historian ? A superstar enemy of plutocratic capitalism who wrote a pathbreaking bestseller, Capital in the 21st Century? Or simply a debonair and generous French intellectual happy to talk redistributive justice? Join this 2020 conversation with John and Adaner Usmani (star of RTB's episode 44: Racism as idea, Racism as Power Relation) to find out. Why did we invite him? John thinks nobody is better than Piketty at mapping and explaining the nature and origin of the glaring and growing inequality that everywhere defines wealth distribution in the 21st century—both between societies and within them. His recent magnum opus, Capital and Ideology. ask what sorts of stories societies (and individuals within those societies) tell themselves so as to tolerate such inequality—and the poverty and misery it produces. Or even to see that inequality as part of the natural order of things. Why did he accept our invitation? A mystery, but who are we to look a gift economist in the mouth? Mentioned in the Episode Philip Larkin, “Why aren't they screaming?” (from the poem “The Old Fools”) Bonus: Here is John's question about his favorite writer, the one Adaner teased him for not asking: “Mr. Piketty, you are interested in hinge points where people cease being captivated by one ideology and begin seeing differently (might one also say, begin being captivated by another ideology?) In 2014, Ursula le Guin said: ‘We live in capitalism. Its power seems inescapable. So did the divine right of kings. Any human power can be resisted and changed by human beings. Resistance and change often begin in art, and very often in our art, the art of words.‘ Can I ask how that resonates with your argument about the rapid changeability of economic paradigms–and moral paradigms for justifying inequality–in Capital and Ideology? “ Read transcript here Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/economics

Is Thomas Piketty the world's most famous economic historian ? A superstar enemy of plutocratic capitalism who wrote a pathbreaking bestseller, Capital in the 21st Century? Or simply a debonair and generous French intellectual happy to talk redistributive justice? Join this 2020 conversation with John and Adaner Usmani (star of RTB's episode 44: Racism as idea, Racism as Power Relation) to find out. Why did we invite him? John thinks nobody is better than Piketty at mapping and explaining the nature and origin of the glaring and growing inequality that everywhere defines wealth distribution in the 21st century—both between societies and within them. His recent magnum opus, Capital and Ideology. ask what sorts of stories societies (and individuals within those societies) tell themselves so as to tolerate such inequality—and the poverty and misery it produces. Or even to see that inequality as part of the natural order of things. Why did he accept our invitation? A mystery, but who are we to look a gift economist in the mouth? Mentioned in the Episode Philip Larkin, “Why aren't they screaming?” (from the poem “The Old Fools”) Bonus: Here is John's question about his favorite writer, the one Adaner teased him for not asking: “Mr. Piketty, you are interested in hinge points where people cease being captivated by one ideology and begin seeing differently (might one also say, begin being captivated by another ideology?) In 2014, Ursula le Guin said: ‘We live in capitalism. Its power seems inescapable. So did the divine right of kings. Any human power can be resisted and changed by human beings. Resistance and change often begin in art, and very often in our art, the art of words.‘ Can I ask how that resonates with your argument about the rapid changeability of economic paradigms–and moral paradigms for justifying inequality–in Capital and Ideology? “ Read transcript here Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/politics-and-polemics

Is Thomas Piketty the world's most famous economic historian ? A superstar enemy of plutocratic capitalism who wrote a pathbreaking bestseller, Capital in the 21st Century? Or simply a debonair and generous French intellectual happy to talk redistributive justice? Join this 2020 conversation with John and Adaner Usmani (star of RTB's episode 44: Racism as idea, Racism as Power Relation) to find out. Why did we invite him? John thinks nobody is better than Piketty at mapping and explaining the nature and origin of the glaring and growing inequality that everywhere defines wealth distribution in the 21st century—both between societies and within them. His recent magnum opus, Capital and Ideology. ask what sorts of stories societies (and individuals within those societies) tell themselves so as to tolerate such inequality—and the poverty and misery it produces. Or even to see that inequality as part of the natural order of things. Why did he accept our invitation? A mystery, but who are we to look a gift economist in the mouth? Mentioned in the Episode Philip Larkin, “Why aren't they screaming?” (from the poem “The Old Fools”) Bonus: Here is John's question about his favorite writer, the one Adaner teased him for not asking: “Mr. Piketty, you are interested in hinge points where people cease being captivated by one ideology and begin seeing differently (might one also say, begin being captivated by another ideology?) In 2014, Ursula le Guin said: ‘We live in capitalism. Its power seems inescapable. So did the divine right of kings. Any human power can be resisted and changed by human beings. Resistance and change often begin in art, and very often in our art, the art of words.‘ Can I ask how that resonates with your argument about the rapid changeability of economic paradigms–and moral paradigms for justifying inequality–in Capital and Ideology? “ Read transcript here Learn more about your ad choices. Visit megaphone.fm/adchoices

Please visit answersincme.com/MMD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in multiple myeloma discuss triplet combination therapies and treatment selection in relapsed/refractory multiple myeloma (RRMM). Upon completion of this activity, participants should be better able to: Explain current guideline recommendations to optimize clinical treatment plans for patients with RRMM; Review the clinical implications of the latest data for triplet regimens containing an anti-CD38 monoclonal antibody, proteasome inhibitors, and chemotherapy in special patient populations with RRMM; and Identify additional monitoring strategies for special patient subgroups with RRMM based on the latest clinical evidence and expert guidance.

SUMAYYA USMANI shares her top 3 cooking tips, hacks and cheats Learn more about your ad choices. Visit podcastchoices.com/adchoices

This week @missj9 is joined by food writer and author Sumayya Usmani as she takes us through 10 things you need to know about Pakistani food and cooking with stories and recipes from her new book Andaza. Learn more about your ad choices. Visit podcastchoices.com/adchoices

This week, Gilly is going to Pakistan, through the memories of food writer and writing coach, Sumayya Usmani Her memoir, Andaza tells the everyday stories about life and food in Karachi. It sees the kitchen as a place where young Pakistani girls learn much more from their mothers and grandmothers than how to make a recipe, but how to feed, how to nurture and how to connect. For Extra Bites accompanying Cooking the Books episodes, go to Gilly's Substack Hosted on Acast. See acast.com/privacy for more information.

7 mins: Advice by Mufti Rafi Usmani Sb Rah to safeguard Iman.

Ulema are Beacons of Guidance. Advice by Mufti Rafi Usmani Sb Rah.

Proceedings from a daylong multitumor educational symposium in partnership with the Florida Cancer Specialists, including key clinical presentations and papers in multiple myeloma. Featuring perspectives from Dr Saad Zafar Usmani, moderated by Dr Neil Love.

This Surah has 11 verses. It takes its name from verse 1: “وَالضُّحَىٰ” (By the morning brightness) where the word “الضحى” meaning “The Morning Brightness” appears. This Surah was revealed in Mecca most probably during the early days of Muhammad's proclamation of his prophethood, and most likely was among the first ten surahs to be revealed. This Surah addressed to Prophet Muhammad and assures him that his Lord had not forgotten him. As discussed in Surah Muddathir, history, ahadith and traditions tell us that the first revelation upon Muhammad was the first five verses of Surah Alaq but than there was a long interval and revelation stopped. This caused much pain and grief to the Prophet. So much so that he tried to reach at the top of the hill to throw himself down, but just when he tried to do so Angel Gabriel appeared and told him that he truly was a Prophet of God and the first experience of revelation was real and not his doubt or his mind's creation. Traditions tell that this was same sort of interval when for a period of time, the revelations stopped. The unbelievers mocked Prophet Muhammad saying that “Muhammad's Lord has abandoned him.” It is recorded in various traditions in Bukhari, Muslim and also by Ahmed bin Hanbal that there was a long interval and Angel Jibril was slow in coming to the Prophet of God PBUH. So the idolaters said, “Muhammad's Lord has abandoned him.” Thus Allah revealed, وَٱلضُّحَىٰ • وَٱلَّيۡلِ إِذَا سَجَىٰ • مَا وَدَّعَكَ رَبُّكَ وَمَا قَلَىٰ By the forenoon. By the night when it darkens. Your Lord has not taken leave of you, [O Muhammad], nor has He detested [you]. On the explanation of “وَلَلْآخِرَةُ خَيْرٌ لَكَ مِنَ الْأُولَىٰ” “And the Hereafter is better for you than the first” It applies on everything and every phase of time of Prophet Muhammad. History proved this verse was a miracle as every next moment for Prophet is this world was better than previous in terms of increase in his followers as well as spreading of message and dominance of Muslims over land and area. Then it also applies similarly to the worldly life of Prophet and hereafter. That's why Prophet was so keen of going from this world that when on his death The Angel of Death told him that Allah Subhan Taalah had given him choice of remaining in this life forever and then going to Paradise or moving on to the company of Allah, he chose that which is with Allah over this world Ahmad bin Hanbal, Tirmidhi, and Ibn Majah recorded a narration from Abdullah bin Masud who said, “The Prophet of God PBUH was lying down on a straw rug, and it left marks on his side. Then when he woke up, he began to rub his side. So I said, O Prophet of God PBUH, will you allow us to spread something soft over this straw rug. He replied, مَالِي وَلِلدُّنْيَا، إِنَّمَا مَثَلِي وَمَثَلُ الدُّنْيَا كَرَاكِبٍ ظَلَّ تَحْتَ شَجَرَةٍ ثُمَّ رَاحَ وَتَرَكَهَا I have nothing to do with this world. The parable of me and this world is like a rider who rests in the shade of a tree, then he passes on and leaves it. --- Send in a voice message: https://anchor.fm/wow-be-podcast/message

Guest: Dr. G. Nahid Usmani Part 2 Dr. Usmani, a Pakistani-born physician, is dedicated to improving medical education in Pakistan. She said her mother inspired her to pursue a career in medicine. Her mother came from a small town in Pakistan, dreamed of a modern college education and became a member of Pakistan's first class of medical graduates. Usmani came to the United States after graduating in 1980 from medical school in Pakistan, where she grew up. She had a fellowship at New York's prestigious Memorial Sloan Kettering Cancer Center and joined UMass in 1999. "It was the warmest, most inviting place I've ever worked," Usmani said of UMass. Usmani followed her mother, Amina, a primary care physician, into medicine, and told a story of a girl who was rebellious from a young age, just like her mother. "My mom was a feminist before there were feminists," said Usmani, one of six children. "She raised her daughters to be independent." When Usmani landed in New York, she said she found the United States to be exactly as she wanted it. She was finally free from objectification of women back at home and able to pursue what she felt was anything she wanted. Her father gave her permission to marry the Harvard student she met only if she first took a qualifying exam for medical school in the U.S. "If someone says I can't do something, I have to do it," she said. For Usmani, she founded the New England chapter of the Association of Physicians of Pakistani Descent of North America. There are an estimated 18,000 to 20,000 such doctors in the United States, Usmani said, and she will lead them as the president-elect of the national group. Usmani has traveled back to Pakistan on a few occasions to help medical students like her. Those trips could be a reminder of what she left behind, with a bomb blast hitting her hospital once and killing one of her patients. She said much of her drive professionally comes from wanting to prove herself and her fellow Pakistanis in the years after the Sept. 11 attacks, when they could be looked at more suspiciously. "I needed to establish a professional identity in this country," she said. -------------------------------------------------------------------------Who is the founder & Owner of LightupwithShua Podcast and LUWS ACADEMY LLC ? visit: lightupwithshua.com I am a student of knowledge of multiple disciplines, a mentor, and an intercultural & Interfaith practitioner, who wants to help heal and solve problems by bringing awareness for conscious living and conscious parenting to people with flexible mindset. Currently hosting a weekly podcast on LightupwithShua podcast on conscious living and parenting. Additionally, actively conducting Self - Healing & Transformation Training Workshops in Pakistan and in the USA. For more information please inquire through email or phone. You can connect with me here: Shua@lightupwithshua.com *Remember to LIKE, SHARE, RATE and REVIEW. Thank you. Shua - شعا ع https://linktr.ee/Shuakhan Copyright © 2017-2022 LUWS ACADEMY LLC & LightupwithShua Podcast All Rights Reserved Attribution-NonCommercial-NoDerivs This work is licensed under a Creative Commons Attribution 4.0 International LicenseLightupwithShua

Guest: Dr. G. Nahid Usmani Part 1 Dr. Usmani, a Pakistani-born physician, is dedicated to improving medical education in Pakistan. She said her mother inspired her to pursue a career in medicine. Her mother came from a small town in Pakistan, dreamed of a modern college education and became a member of Pakistan's first class of medical graduates. Usmani came to the United States after graduating in 1980 from medical school in Pakistan, where she grew up. She had a fellowship at New York's prestigious Memorial Sloan Kettering Cancer Center and joined UMass in 1999. "It was the warmest, most inviting place I've ever worked," Usmani said of UMass. Usmani followed her mother, Amina, a primary care physician, into medicine, and told a story of a girl who was rebellious from a young age, just like her mother. "My mom was a feminist before there were feminists," said Usmani, one of six children. "She raised her daughters to be independent." When Usmani landed in New York, she said she found the United States to be exactly as she wanted it. She was finally free from objectification of women back at home and able to pursue what she felt was anything she wanted. Her father gave her permission to marry the Harvard student she met only if she first took a qualifying exam for medical school in the U.S. "If someone says I can't do something, I have to do it," she said. For Usmani, she founded the New England chapter of the Association of Physicians of Pakistani Descent of North America. There are an estimated 18,000 to 20,000 such doctors in the United States, Usmani said, and she will lead them as the president-elect of the national group. Usmani has traveled back to Pakistan on a few occasions to help medical students like her. Those trips could be a reminder of what she left behind, with a bomb blast hitting her hospital once and killing one of her patients. She said much of her drive professionally comes from wanting to prove herself and her fellow Pakistanis in the years after the Sept. 11 attacks, when they could be looked at more suspiciously. "I needed to establish a professional identity in this country," she said. ----------------------------------------------------------------   Who is the founder & Owner of LightupwithShua Podcast and LUWS ACADEMY LLC ? visit: lightupwithshua.com I am a student of knowledge of multiple disciplines, a mentor, and an intercultural & Interfaith practitioner, who wants to help heal and solve problems by bringing awareness for conscious living and conscious parenting to people with flexible mindset. Currently hosting a weekly podcast on LightupwithShua podcast on conscious living and parenting. Additionally, actively conducting Self - Healing & Transformation Training Workshops in Pakistan and in the USA. For more information please inquire through email or phone. You can connect with me here: Shua@lightupwithshua.com *Remember to LIKE, SHARE, RATE and REVIEW. Thank you. Shua - شعا ع https://linktr.ee/Shuakhan Copyright © 2017-2022 LUWS ACADEMY LLC & LightupwithShua Podcast All Rights Reserved Attribution-NonCommercial-NoDerivs This work is licensed under a Creative Commons Attribution 4.0 International LicenseLightupwithShua

Heart touching, Beautiful recitation of Surah Waqiah with Urdu translation. Urdu translation by: Mufti Taqi Usmani Voice Over by : Wasif Burney Jazak Allah Khair for watching this video. Surah Waqiah is the 56th Surah of the Quran. It has:- No. of verses: 96 No. of Rukus: 3 Other names: The Event, The Inevitable Position: Juzʼ 27 Classification: Meccan The afterlife (akhirah) is the main topic discussed in the chapter. Picking up from the preceding chapter, Ar-Rahman, which discusses the rewards of Paradise (jannah), this chapter also mentions them and then contrasts them with the punishment of hell. The chapter also distinguishes the three classes of people in the afterlife, "the foremost", "the companions of the right" and "the companions of the left": the first two groups will enter paradise while the companions of the left will go to hell. Here, "the right" is associated with goodness, the righteous will be seated to the right of God's throne and receive their records of deeds in their right hand. The "foremost" refers to a special group of people who will have an even better fate than the companions of the right in the afterlife. Quranic commentators differ on understanding who the foremost is. They variously identify the foremost with the prophets, the saints, the truthful, the martyrs, the first to accept Islam, and others. This beautiful recitation of the Quran with Urdu - Hindi translation is made so the viewer can understand what Allah says in the Quran. It will help Muslims to learn about Islam and to increase their daily practices in a way which Allah defined for us. Contribute today by sharing and subscribing to this channel for Sadaqah Jariyah. Thank you for your support. The recitation uploaded here is to share the Urdu translation. May Allah purify my intentions, make it solely for his sake, and forgive my shortcomings. #surahwaqiah #surahwaqia #surahwaqiahfull #waqiah #quranwithurdutranslation --- Send in a voice message: https://anchor.fm/wow-be-podcast/message

Saad Z. Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY Recorded on September 30, 2022 Join us for this special episode, recorded live from the Tenth Annual Meeting of the Society of Hematologic Oncology in Houston, TX! Guest host and conference attendee, Lauren Berger, Senior Director of Professional Education and Engagement at The Leukemia & Lymphoma Society, speaks with Dr. Saad Usmani, from Memorial Sloan Kettering Cancer Center, about his insights into the progress in immunotherapies in blood cancers shared at the conference. Not able to attend SOHO? Learn more about what was shared at the conference by tuning in here! 

Surah Al Muzammil is the 73rd Surah of the Holy Quran and is found in 29th para. This Surah was revealed in Makkah so it is referred to as “Makki” Surah and contains 20 verses, 227 Words, and 847 letters. The person who recites Surah Al Muzammil in the Isha prayer or Tahajjud will get a pure heart and dies in the state of purity. It is said by the Holy Prophet (peace be upon him) that a person who recites Surah al Muzammil will not experience any worst situation or time. It is narrated by Imam Jafar as Sadiq (R.A) that a person who recites this Surah and asks for something from Allah, will get it. Produced by Wow Be Creatives For Wow Be Podcast --- Send in a voice message: https://anchor.fm/wow-be-podcast/message

Surah e Al Rahman with Urdu Translation | Recitation Qari Abdul Samad | Urdu Translation Mufti Taqi Usmani | Urdu Voice Over Wasif Burney Produced by Wow Be Creatives --- Send in a voice message: https://anchor.fm/wow-be-podcast/message

Are you trying to figure out how to create a pre-recorded course, but wondering what steps you need to take to make it a reality?This episode's guest, Sumayya Usmani, found herself in that same position last year. Now, she has an incredible pre-recorded course teaching people instinctual cooking through her native Pakistani cuisine. You're going to love hearing how she got from point A to point B, thanks to her time in Cooking Class Business School…it's quite the story!Sumayya is the author of two award-winning cookbooks, Summers Under the Tamarind Tree and Mountain Berries & Desert Spice. She is also the creator of Sabzi, which draws from her Pakistani heritage to teach students how to create beautiful, vegetarian Pakistani dishes based on classic recipes without losing flavor.In this episode, Sumayya offers insight into how she transitioned from a career in law to writing award-winning cookbooks and creating her online course. She also shares how Cooking Class Business School gave her the direction she needed to create Sabzi and the practical steps she took to get it from just a dream to a real course with real students!If you know you have skills to offer and want to teach a pre-recorded class, but don't know where to start, you're in the right place. You're going to eat up this episode!SUBSCRIBE, RATE & REVIEW:Did this episode get you excited about teaching your own course? Do you want to hear about CCBS? Help The Experiential Table grow by subscribing, rating, and reviewing this podcast!HELPFUL LINKS:Connect with Sumayya on InstagramVisit Sumayya's websiteSign up for Sumayya's newsletter and get the 3 secrets of Pakistani cookingJoin the waitlist for SavouredRegister for my free masterclass, The 4-Step Framework For Profitable Online Cooking ClassesJoin The Experiential Table Facebook groupRead the Episode TranscriptSay hello to me on Instagram